IGM Biosciences (IGMS) just unveiled an announcement.
At IGM Biosciences, Inc.’s 2024 annual meeting, a strong majority of stockholders participated, with nearly 90% of shares represented. They elected three Class II directors, ratified Deloitte & Touche LLP as their independent accounting firm for the year, approved an amendment limiting officer liability, and endorsed an employee stock option exchange program. These approvals underscore the shareholders’ active involvement and support for the company’s governance and compensation strategies.
Learn more about IGMS stock on TipRanks’ Stock Analysis page.
